Loratadine/montelukast
Alternative Names: Claritin/Singulair; Montelukast/loratadineLatest Information Update: 22 Mar 2010
At a glance
- Originator Schering-Plough/Merck Pharmaceuticals
- Class Acetates; Antiallergics; Antiasthmatics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Quinolines
- Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 27 Jun 2008 Schering-Plough/Merck Pharmaceuticals withdraws NDA for loratadine/montelukast in Seasonal allergic rhinitis
- 25 Apr 2008 Schering-Plough/Merck Pharmaceuticals receives non-approvable letter from the FDA for loratadine/montelukast in Seasonal allergic rhinitis
- 30 Aug 2007 Preregistration for Seasonal allergic rhinitis in USA (PO), FDA has accepted filing